Good evening :)
$
₹
Eli Lilly and Company

Eli Lilly and Company

LLY

NYSE
Asset Logo

Eli Lilly and Company

LLY

NYSE
$1,273.902.50% (-32.78)
$
₹
$1,273.902.50% (-32.78)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - General

Mega Cap

With a market cap of $1.1T the stock is ranked 14

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

43.09
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

30.28
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$29.49
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

1.13
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

33.53%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

0.5%

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 31 analysts reports

Buy
26 analysts
Hold
3 analysts
Sell
2 analysts

Price Upside

+4.56%

Earnings Growth

+42.86%

Rev. Growth

+36.06%

See Detailed Forecast

Company Profile

Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
39.11
39.11
1Y Return
37.93%
37.93%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
118.95
118.95
1Y Return
66.63%
66.63%
Buy Reco %
70.37
70.37
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
23.25
23.25
1Y Return
14.79%
14.79%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
25.17
25.17
1Y Return
1.93%
1.93%
Buy Reco %
83.33
83.33
Novo Nordisk A/S
NVO
Novo Nordisk A/S
P/E Ratio
9.55
9.55
1Y Return
26.63%
26.63%
Buy Reco %
21.42
21.42
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 4.56% growth, versus a trailing 3-year CAGR of 30.91%.

2026
Current$1,273.46Baseline
Analyst Target - 1 year
Target$1,331.55+4.56%

All values in $

202220232024202520262027$607.32$893.11$1178.91Target+4.56%
2026
Current$1,273.46Baseline
Analyst Target - 1 year
Target$1,331.55+4.56%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 36.06% growth, versus a trailing 3-year CAGR of 31.69%.

2025
Current$65.17Baseline
Forecast for Dec 2026
High$91.61+40.57%
Average$88.68+36.06%
Low$83.42+28%

All values in $ Billion

20212022202320242025202628.3128.5434.1245.0465.17Low+28%Average+36.06%High+40.57%
2025
Current$65.17Baseline
Forecast for Dec 2026
High$91.61+40.57%
Average$88.68+36.06%
Low$83.42+28%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

Lower earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 42.86% growth, versus a trailing 3-year CAGR of 45.01%.

2025
Current$24.21Baseline
Forecast for Dec 2026
High$38.56+59.27%
Average$34.59+42.86%
Low$31.33+29.41%

All values in $

2021202220232024202520268.177.946.321324.21Low+29.41%Average+42.86%High+59.27%
2025
Current$24.21Baseline
Forecast for Dec 2026
High$38.56+59.27%
Average$34.59+42.86%
Low$31.33+29.41%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

17.6
5.5
19.2
6.6
19.7
7.3
22.9
7
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue8.7611.3011.4313.5312.7215.5517.6019.2919.7922.97
Net Income2.242.960.974.402.755.665.586.637.397.09
Net Profit Margin25.58%26.25%8.48%32.58%21.67%36.38%31.71%34.40%37.35%30.88%
See CostsAll values in $ Billion

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - General

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Eli Lilly and Company 43.0930.281.13
Johnson & Johnson39.117.632.82
Merck & Company Inc118.958.712.70
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare LLY with any stock or ETF
Compare LLY with any stock or ETF
Comparing from
LLY
JNJ
MRK
Loading...

Frequently asked questions

  1. Eli Lilly and Company (LLY) share price today is $1,273.90 as of October 24, 2026 at 1:29 AM IST. The stock touched a day high of $1,305.31 and a day low of $1,259.24.

  2. Eli Lilly and Company stock trades on NYSE under the ticker symbol LLY.

  3. Eli Lilly and Company's market capitalization is $1.13T as of October 24, 2026 at 1:29 AM IST.

  4. Eli Lilly and Company's price-to-earnings (P/E) ratio is 43.09 as of October 24, 2026.

  5. Eli Lilly and Company's price-to-book (P/B) ratio is 30.28 as of October 24, 2026.

  6. Yes, Eli Lilly and Company pays a dividend, with a current dividend yield of 0.5%.

  7. Yes, You can buy Eli Lilly and Company shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  8. Indian investors can buy Eli Lilly and Company shares in three steps: 1. Search Eli Lilly and Company on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  9. Since Eli Lilly and Company trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  10. Indian investors can start investing in Eli Lilly and Company (LLY) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0078 shares at the current price of $1,273.90.

Loading...